NYSE:ENZ - Enzo Biochem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.95 -0.32 (-9.79 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$3.27
Today's Range$2.92 - $3.25
52-Week Range$2.92 - $9.06
Volume275,463 shs
Average Volume163,617 shs
Market Capitalization$152.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing ‘STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ENZ
Previous Symbol
CUSIPN/A
Phone212-583-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.12
Quick Ratio3.76

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$104.71 million
Price / Sales1.33
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.72 per share
Price / Book1.72

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-10,320,000.00
Net Margins-9.86%
Return on Equity-13.25%
Return on Assets-10.75%

Miscellaneous

Employees503
Outstanding Shares47,180,000
Market Cap$152.40 million
OptionableOptionable

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) announced its quarterly earnings data on Monday, December, 10th. The medical research company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The medical research company earned $21.26 million during the quarter. Enzo Biochem had a negative net margin of 9.86% and a negative return on equity of 13.25%. View Enzo Biochem's Earnings History.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Enzo Biochem.

Has Enzo Biochem been receiving favorable news coverage?

Media stories about ENZ stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enzo Biochem earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani Ph.D., Co-Founder, Chairman, CEO & Sec. (Age 75)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 68)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 52)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 60)
  • Dr. Dieter Schapfel, Chief Medical Director (Age 55)

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Evermore Global Advisors LLC (9.67%), Evermore Global Advisors LLC (7.76%), Renaissance Technologies LLC (6.28%), Vanguard Group Inc. (5.76%), Dimensional Fund Advisors LP (4.33%) and The Manufacturers Life Insurance Company (4.19%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Bruce A Hanna, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Which major investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Evermore Global Advisors LLC, GSA Capital Partners LLP, Renaissance Technologies LLC, AQR Capital Management LLC, TIAA CREF Investment Management LLC, Acadian Asset Management LLC and Corrado Advisors LLC. Company insiders that have sold Enzo Biochem company stock in the last year include Barry W Weiner and Elazar Rabbani. View Insider Buying and Selling for Enzo Biochem.

Which major investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., The Manufacturers Life Insurance Company , Marshall Wace LLP, Algert Global LLC, Assenagon Asset Management S.A., Marathon Capital Management, Bridgeway Capital Management Inc. and Dimensional Fund Advisors LP. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna and Elazar Rabbani. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.95.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $152.40 million and generates $104.71 million in revenue each year. Enzo Biochem employs 503 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is http://www.enzo.com.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.


MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel